Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19020628 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18999662 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18941137 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18775916 | CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE | July 2024 | October 2024 | Abandon | 3 | 1 | 0 | No | No |
| 18633460 | COMPOUNDS AS MYT1 INHIBITORS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18612156 | IRAK4 Inhibitors | March 2024 | July 2024 | Allow | 4 | 0 | 0 | No | No |
| 18601926 | METHODS OF USING DMT | March 2024 | June 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18437931 | EPINEPHRINE COMPOSITIONS AND CONTAINERS | February 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | Yes |
| 18077431 | DOSING REGIMENS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZIN-1-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE FOR TREATMENT OF INDOLENT SYSTEMIC MASTOCYTOSIS | December 2022 | November 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 18060864 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | December 2022 | April 2023 | Allow | 4 | 1 | 0 | No | No |
| 17972633 | Polyherbal Self Micro-Emulsifying Delivery System (SMEDS) composition for multi-disease treatment | October 2022 | November 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17822438 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | August 2022 | December 2023 | Allow | 16 | 1 | 0 | No | No |
| 17819157 | MULTI-TARGETED TYROSINE KINASE INHIBITORS EFFECTIVE IN ANTITUMOR USES | August 2022 | April 2024 | Allow | 20 | 2 | 0 | No | No |
| 17885493 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17815400 | PROCESSES FOR PREPARING TUCATINIB POLYMORPHS | July 2022 | February 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17862865 | CRYSTALLINE FORMS OF TROFINETIDE | July 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17842372 | STABLE TRYPTAMINE ORAL FILMS | June 2022 | June 2025 | Allow | 36 | 3 | 0 | No | No |
| 17836089 | Process for Producing A Vegan Cannabinoid Chewy | June 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17835480 | SOLID FORMS OF PONATINIB HYDROCHLORIDE AND PROCESS THEREOF | June 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17833113 | METHOD FOR PREPARING NICOTINAMIDE MONONUCLEOTIDE COCRYSTAL | June 2022 | January 2024 | Allow | 19 | 0 | 0 | No | No |
| 17829933 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | June 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17663760 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATION AND ANTIPSYCHOTICS | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17732018 | DESIGN AND SYNTHESIS OF DUAL 5-HT1A AND 5-HT7 RECEPTOR LIGANDS | April 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17730395 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | April 2022 | March 2023 | Allow | 10 | 0 | 0 | No | No |
| 17727532 | CANNABINOID EMULSION COMPOSITION AND METHOD OF MANUFACTURING | April 2022 | July 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17723758 | GLP-1R MODULATING COMPOUNDS | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17713455 | Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer | April 2022 | August 2024 | Allow | 28 | 2 | 1 | No | No |
| 17708072 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | March 2022 | June 2023 | Allow | 14 | 0 | 0 | No | No |
| 17704789 | Use of ZT-1A and Analogs Thereof to Prevent and/or Treat Neurodegenerative and Neurocognitive Disorders | March 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17699082 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | March 2022 | December 2023 | Allow | 21 | 1 | 1 | No | No |
| 17698956 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | March 2022 | July 2023 | Allow | 16 | 2 | 0 | No | No |
| 17696279 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASE | March 2022 | December 2024 | Allow | 33 | 1 | 0 | No | No |
| 17688369 | PTGR2 INHIBITORS AND THEIR USE | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17677698 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | February 2022 | October 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17588173 | METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS | January 2022 | September 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17586751 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2022 | November 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17571105 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING NEUROCOGNITIVE DISORDERS | January 2022 | January 2025 | Allow | 36 | 4 | 0 | No | No |
| 17560048 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | December 2021 | August 2023 | Allow | 20 | 2 | 0 | No | No |
| 17556295 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17548161 | METHODS OF TREATING PROSTATE CANCER | December 2021 | January 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17540653 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION USING MODIFIED FORMS OF TRIMETAZIDINE | December 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17540646 | METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE | December 2021 | April 2024 | Allow | 29 | 3 | 0 | No | No |
| 17528342 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | November 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17486123 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF | September 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17483234 | POLYSORBATE MIXTURES HAVING MODIFIED FATTY ACID ESTER DISTRIBUTION | September 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17470243 | Method for Treating Pruritus | September 2021 | December 2024 | Allow | 39 | 3 | 0 | No | No |
| 17408956 | Inhibitors of SARM1 | August 2021 | October 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17445588 | COMPOUNDS AS GLP-1R AGONISTS | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17429831 | PYRIDAZINIUM COMPOUNDS FOR USE IN A METHOD OF CONTROLLING UNWANTED PLANT GROWTH | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427831 | 2-AMINOQUINAZOLINONE DERIVATIVE | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17373707 | BRANCHED AMINO ACID SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS | July 2021 | August 2023 | Allow | 25 | 2 | 0 | No | No |
| 17354751 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | June 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17416222 | C-TERMINAL SRC KINASE INHIBITORS | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17347823 | ANTIMICROBIAL, ANTIVIRAL OR BIOCIDE COATING COMPOSITIONS | June 2021 | July 2023 | Allow | 25 | 0 | 1 | No | No |
| 17303845 | CRYSTALLINE ALK5 INHIBITORS AND USES THEREOF | June 2021 | December 2023 | Allow | 30 | 1 | 0 | No | No |
| 17297100 | TEAT DISINFECTANT COMPOSITION | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17296008 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17295153 | AQUEOUS SOLUTIONS OF POORLY SOLUBLE PESTICIDES USING POLYALKYOXYLATED ALCOHOLS | May 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17313977 | TREATMENTS FOR COVID-19-RELATED SYSTEMIC SCLEROSIS, VASCULAR INSUFFICIENCY, DISTAL ISCHEMIA, AND RELATED DISEASE CONDITIONS | May 2021 | August 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17288258 | METHODS AND MATERIALS FOR TREATING NEUROPSYCHIATRIC DISORDERS | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17287492 | WDR5 INHIBITORS AND MODULATORS | April 2021 | January 2024 | Allow | 33 | 0 | 0 | No | No |
| 17285918 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | April 2021 | December 2023 | Allow | 32 | 1 | 0 | No | No |
| 17285889 | PHARMACEUTICAL CRYSTAL OF CONTEZOLID ACEFOSAMIL, PREPARATION METHOD THEREFOR, AND USES THEREOF | April 2021 | June 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17285064 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | April 2021 | January 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17226356 | H2O CRYSTAL FORMS OF A TCA CYCLE INTERMEDIATE CONJUGATE | April 2021 | August 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17273510 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | March 2021 | April 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17185750 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | February 2021 | June 2023 | Allow | 27 | 0 | 0 | No | No |
| 17268406 | INTEGRIN ANTAGONISTS | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17267885 | Process for Manufacturing Pibrentasvir Active Drug Substance | February 2021 | November 2023 | Allow | 33 | 0 | 0 | No | No |
| 17163010 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | January 2021 | May 2024 | Allow | 40 | 2 | 1 | No | No |
| 17259451 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | January 2021 | April 2024 | Allow | 39 | 2 | 0 | No | No |
| 17256330 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | December 2020 | March 2024 | Allow | 39 | 1 | 0 | No | No |
| 17126364 | COMPLEX, CONTRAST AGENT AND METHOD FOR TREATING A DISEASE RELATED TO CXCR4 RECEPTOR | December 2020 | January 2024 | Allow | 37 | 1 | 0 | No | No |
| 17051016 | OPHTHALMIC COMPOSITIONS COMPRISING TAFLUPROST FOR THE TREATMENT OF GLAUCOMA | October 2020 | August 2024 | Allow | 46 | 2 | 0 | No | No |
| 17047961 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | October 2020 | July 2024 | Allow | 45 | 2 | 1 | No | No |
| 17045150 | ISOTHERMAL REACTIVE CRYSTALLISATION PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF PIMODIVIR HYDROCHLORIDE HEMIHYDRATE | October 2020 | November 2022 | Allow | 26 | 0 | 0 | No | No |
| 17043134 | TREATMENT OF TRK-ASSOCIATED CANCERS | September 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17028824 | Compositions of Δ10-THC and Δ6a10-THC | September 2020 | January 2024 | Abandon | 39 | 1 | 1 | No | No |
| 16981916 | COMPOSITION FOR PREVENTING AND TREATING BREAST CANCER INCLUDING SELENOPSAMMAPLIN A AS ACTIVE INGREDIENTS | September 2020 | December 2023 | Allow | 39 | 2 | 0 | No | No |
| 17021698 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | September 2020 | April 2024 | Abandon | 43 | 1 | 1 | No | No |
| 16651004 | R-KETAMINE AND DERIVATIVE THEREOF AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATION DISEASE OR RECOGNITION FUNCTIONAL DISORDER | September 2020 | January 2024 | Abandon | 46 | 3 | 0 | No | No |
| 16978248 | CRYSTALLINE FORMS OF VENETOCLAX | September 2020 | August 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16977200 | WATER-SOLUBLE PHYTOCANNABINOID FORMULATIONS | September 2020 | October 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16975818 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | August 2020 | September 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16975600 | CRYSTAL FORM AND SALT FORM OF PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR | August 2020 | September 2022 | Allow | 34 | 0 | 0 | No | No |
| 16914100 | COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS | June 2020 | August 2023 | Allow | 38 | 1 | 1 | No | No |
| 16850613 | METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2 | April 2020 | June 2024 | Abandon | 50 | 2 | 1 | No | No |
| 15712515 | STABLE CANNABINOID FORMULATIONS | September 2017 | September 2023 | Allow | 60 | 6 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner TRAN, ERIC works in Art Unit 1629 and has examined 80 patent applications in our dataset. With an allowance rate of 67.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner TRAN, ERIC's allowance rate of 67.5% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TRAN, ERIC receive 1.32 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by TRAN, ERIC is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +36.6% benefit to allowance rate for applications examined by TRAN, ERIC. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 43.6% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 53.3% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.8% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.